Alzheimer’s is a multifaceted disease, particularly in its sporadic, late-onset form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and inflammation—contribute to a ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

The brain shrinkage seen on amyloid immunotherapy remains an unsolved and concerning riddle. At the Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, Nick Fox ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

People with ApoE3 Christchurch variant stave off even autosomal-dominant Alzheimer’s disease by keeping neurofibrillary tangles at bay. Could people born without this protective mutation reap its ...

Change was in the air at the Alzheimer’s Association International Conference, held July 16-20 in Amsterdam. With the first treatment in 20 years having just earned traditional approval from the U.S.

How does gene expression in the brain change with age? The answer remains murky, because the field has lacked a systematic, brain-wide survey of alterations across the lifespan. Researchers led by ...

How the brain’s intricate vasculature deteriorates during Alzheimer’s disease has only recently come into focus, thanks to advances in isolating and studying cerebrovascular cells. In a single-nucleus ...

Otsuka Pharmaceutical Co. Ltd. and Lundbeck LLC announced on May 10 that their D2 dopamine receptor agonist, brexpiprazole, aka Rexulti, had been approved by the U.S. Food and Drug Administration for ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...